Cargando…
E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma: A phase I study
E7777, a recombinant cytotoxic fusion protein comprising diphtheria toxin fragments A and B and human interleukin‐2, shares an amino acid sequence with denileukin diftitox but has improved purity and an increased percentage of active protein monomer species. A phase I study was carried out to evalua...
Autores principales: | Ohmachi, Ken, Ando, Kiyoshi, Ogura, Michinori, Uchida, Toshiki, Tobinai, Kensei, Maruyama, Dai, Namiki, Masayuki, Nakanishi, Tadashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834772/ https://www.ncbi.nlm.nih.gov/pubmed/29363235 http://dx.doi.org/10.1111/cas.13513 |
Ejemplares similares
-
Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma
por: Kawai, Hidetsugu, et al.
Publicado: (2021) -
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
por: Munakata, Wataru, et al.
Publicado: (2021) -
Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Ogura, Michinori, et al.
Publicado: (2013) -
Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma
por: Ogura, Michinori, et al.
Publicado: (2014) -
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
por: Munakata, Wataru, et al.
Publicado: (2022)